This topic contains 8 replies, has 6 voices, and was last updated by Suzanne McGettigan June 11, 2018 at 2:29 pm.

Viewing 9 posts - 1 through 9 (of 9 total)
  • Author
    Posts
  • #4805
    Expert Nurse
    Mollie Reed
    Mollie Reed

    What are your thoughts on the Phase III trial with pembro plus Epacadostat not reaching its endpoint? I feel like we had a lot of patients that did quite well on it, though I suppose those might be the patients that would have responded just as well to single agent PD-1. Have you all had a lot of questions about this trial from patients?

    #4813
    Expert Nurse
    Virginia Seery
    Virginia Seery

    Surprisingly, we have not had many patients asking us about this trial. I know going into it there was a lot of excitement about the combination so we were surprised it did not reach its endpoint.

    #4814
    Expert Nurse
    Mollie Reed
    Mollie Reed

    Yeah…..I guess we still had patients on it in the phase 1 setting that were eager. They’ve obviously done well if still on it in Phase 1, but I think some of them were hoping it would be approved so they could get through local oncologist.

    #4819
    Expert Nurse
    Lisa Kottschade
    Lisa Kottschade

    The results of this trial were quite striking, especially with strong Phase I/II data. There is some thought that the dose of the IDO inhibitor may have been too low. Was very disappointing as this may have been a good alternative to dual ICI therapy in those that tolerability was questionable.

    #4820
    Expert Nurse
    Krista Rubin
    Krista Rubin

    We have been spoiled lately; in that so many treatment options for melanoma have become available in the recent years. We have not been disappointed by trial results in quite a while (thankfully). Perhaps this is a reminder to all of us that indeed, melanoma remains a difficult to treat malignancy.

    #4825
    Expert Nurse
    Mollie Reed
    Mollie Reed

    So true! We have been SO fortunate to have gained such ground in melanoma over the last several years!

    #4835
    Expert Nurse
    Mollie Reed
    Mollie Reed

    We’re now having to notify patients that the trial didn’t reach its endpoint and take them off the IDO. This is really tough for those patients that have been on this in Phase 1 for quite some time……especially considering that some did REALLY WELL!

    #4849
    Expert Nurse
    Rajni Kannan
    Rajni Kannan

    We were just discussing this last week. After years of ASCO having huge announcements of positive very influential findings things have slowed down. With the discovery of Ipilimumab and Nivolumab and the BRAF/MEK inhibitors we are almost at a plateau when it comes to new innovations. I am sure there are many more to come but at the moment especially front line clinical trials seems to be limited.

    #4850
    Expert Nurse
    Suzanne McGettigan
    Suzanne McGettigan

    Rajni–
    such a good point.
    In the melanoma world, we have been lulled into this sense that every year there will be new treatments for melanoma. The last five years have been amazing, with so many new therapies and new combinations of therapies that have truly changed the way we manage melanoma. This year was the first in which it seemed like it slowed down.

Viewing 9 posts - 1 through 9 (of 9 total)

You must be logged in to reply to this topic.